Full Text
PCN9 ERLOTINIB IN NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY–A COST-SAVING SECOND-LINE TREATMENT OPTION?

Abstract

Authors

A Gabriel O Pirk W Kotowa

Back to Volume 9, Issue 6
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×